395 related articles for article (PubMed ID: 11669216)
1. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
Akpek G; Lee SM; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
3. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
4. Chronic graft-versus-host disease: a prospective cohort study.
Arora M; Burns LJ; Davies SM; Macmillan ML; Defor TE; Miller WJ; Weisdorf DJ
Biol Blood Marrow Transplant; 2003 Jan; 9(1):38-45. PubMed ID: 12533740
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
8. The effect of budesonide mouthwash on oral chronic graft versus host disease.
Sari I; Altuntas F; Kocyigit I; Sisman Y; Eser B; Unal A; Fen T; Ferahbas A; Ozturk A; Unal A; Cetin M
Am J Hematol; 2007 May; 82(5):349-56. PubMed ID: 17109390
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
[TBL] [Abstract][Full Text] [Related]
10. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation.
Atsuta Y; Suzuki R; Yamamoto K; Terakura S; Iida H; Kohno A; Naoe T; Yano K; Wakita A; Taji H; Hamaguchi M; Kodera Y; Sao H; Morishima Y; Hamajima N; Morishita Y
Bone Marrow Transplant; 2006 Feb; 37(3):289-96. PubMed ID: 16400341
[TBL] [Abstract][Full Text] [Related]
11. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
12. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
Wang Y; Xu LP; Liu DH; Chen H; Chen YH; Han W; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2009 Apr; 15(4):505-11. PubMed ID: 19285639
[TBL] [Abstract][Full Text] [Related]
13. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
14. A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease.
Gaziev D; Lucarelli G; Polchi P; Angelucci E; Galimberti M; Giardini C; Baronciani D; Erer B; Sodani P
Bone Marrow Transplant; 2001 Jan; 27(1):45-51. PubMed ID: 11244437
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR
Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.
Andree H; Hilgendorf I; Leithaeuser M; Junghanss C; Holzhueter S; Loddenkemper C; Steiner B; Freund M; Wolff D
Bone Marrow Transplant; 2008 Oct; 42(8):541-6. PubMed ID: 18641680
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease.
Ilhan O; Arat M; Arslan O; Ayyildiz E; Sanli H; Beksac M; Ozcan M; Gürman G; Akan H
Transfus Apher Sci; 2004 Jun; 30(3):185-7. PubMed ID: 15172621
[TBL] [Abstract][Full Text] [Related]
19. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
20. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.
Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
